Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency.

Structure-activity studies on the oxytocin antagonist 1 (L-371,257; Ki = 9.3 nM) have led to the identification of a related series of compounds containing an ortho-trifluoroethoxyphenylacetyl core which are orally bioavailable and have significantly improved potency in vitro and in vivo, e.g., compound 8 (L-374,943; Ki = 1.4 nM).

[1]  D. Veber,et al.  1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist. , 1995, Journal of medicinal chemistry.

[2]  R. Volante,et al.  Regioselective nucleophilic substitutions of fluorobenzene derivatives , 1996 .

[3]  S Vickers,et al.  Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines. , 1998, Journal of medicinal chemistry.

[4]  B. E. Evans,et al.  1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. , 1994, Journal of medicinal chemistry.

[5]  R M Freidinger,et al.  Nonpeptide oxytocin antagonists: potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridyl)ethyl ether terminus. , 1998, Bioorganic & medicinal chemistry letters.

[6]  J. Jasper,et al.  Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. , 1995, Life sciences.

[7]  B. E. Evans,et al.  L‐368,899, a potent orally active oxytocin antagonist for potential use in preterm labor , 1993 .

[8]  A. Mckillop,et al.  Thallium in organic synthesis. XXXIII. One-step synthesis of methyl arylacetates from acetophenones using thallium(III) nitrate (TTN) , 1973 .